Activation of prelimbic 5-HT1A receptors produces antidepressant-like effects in a unilateral rat model of Parkinson's disease

Neuroscience. 2014 May 30:268:265-75. doi: 10.1016/j.neuroscience.2014.03.033. Epub 2014 Mar 26.

Abstract

Depression is a common symptom in Parkinson's disease (PD), but its pathophysiology remains unclear. Several lines of studies have revealed that the prelimbic (PrL) sub-region of the ventral medial prefrontal cortex and 5-HT1A receptors are involved in the regulation of depression. In this study, we examined whether complete unilateral lesions of the medial forebrain bundle (MFB) using 6-hydroxydopamine in rats are able to induce depressive-like behaviors, the role of PrL 5-HT1A receptors in the regulation of these behaviors, and co-localization of 5-HT1A receptor and neuronal glutamate transporter EAAC1-immunoreactive (EAAC1-ir) neurons in the PrL. The MFB lesions induced depressive-like responses as measured by the sucrose preference and forced swim tests when compared to sham-operated rats. The intra-PrL injection of 5HT1A receptor agonist 8-OH-DPAT (50, 100, and 500ng/rat) increased sucrose consumption, and decreased immobility time in both sham-operated and the lesioned rats, indicating the induction of antidepressant effects. Furthermore, the intra-PrL injection of 5HT1A receptor antagonist WAY-100635 (60, 120, and 240ng/rat) showed a decrease in sucrose consumption, and an increase in immobility time, indicating the induction of depressive-like responses. However, the effective doses in the lesioned rats were higher than those in sham-operated rats, which attribute to down-regulation of 5-HT1A receptor expression on EAAC1-ir neurons in the PrL of the lesioned rats. These findings suggest that unilateral lesions of the MFB in rats may induce depressive-like behaviors, and 5-HT1A receptors of the PrL play an important role in the regulation of these behaviors.

Keywords: 5-HT(1A) receptors; Parkinson’s disease; depression; prelimbic medial prefrontal cortex; rat.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Hydroxy-2-(di-n-propylamino)tetralin / pharmacology
  • Animals
  • Antidepressive Agents / pharmacology
  • Depression / drug therapy
  • Depression / physiopathology*
  • Dietary Sucrose / administration & dosage
  • Dose-Response Relationship, Drug
  • Down-Regulation
  • Excitatory Amino Acid Transporter 3 / metabolism
  • Food Preferences / drug effects
  • Food Preferences / physiology
  • Male
  • Medial Forebrain Bundle / drug effects
  • Medial Forebrain Bundle / physiopathology*
  • Neurons / drug effects
  • Neurons / physiology
  • Oxidopamine
  • Parkinsonian Disorders / physiopathology*
  • Parkinsonian Disorders / psychology*
  • Piperazines / pharmacology
  • Pyridines / pharmacology
  • Rats, Sprague-Dawley
  • Receptor, Serotonin, 5-HT1A / metabolism*
  • Serotonin 5-HT1 Receptor Antagonists / pharmacology
  • Serotonin Receptor Agonists / pharmacology

Substances

  • Antidepressive Agents
  • Dietary Sucrose
  • Excitatory Amino Acid Transporter 3
  • Piperazines
  • Pyridines
  • Serotonin 5-HT1 Receptor Antagonists
  • Serotonin Receptor Agonists
  • Slc1a1 protein, rat
  • Receptor, Serotonin, 5-HT1A
  • N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide
  • 8-Hydroxy-2-(di-n-propylamino)tetralin
  • Oxidopamine